PD1 signal transduction pathways in T cells

Hugo Arasanz, Maria Gato-Cañas, Miren Zuazo, Maria Ibañez-Vea, Karine Breckpot, Grazyna Kochan, David Escors

Research output: Contribution to journalScientific review

123 Citations (Scopus)


The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.

Original languageEnglish
Pages (from-to)51936-51945
Number of pages10
Issue number31
Publication statusPublished - 7 Feb 2017


  • B7-H1
  • Cancer
  • PD-L1
  • PD1
  • PDL1


Dive into the research topics of 'PD1 signal transduction pathways in T cells'. Together they form a unique fingerprint.

Cite this